You are subscribed to What's New at CBER for U.S. Food & Drug Administration (FDA).
This page has been updated recently.
FDA develops alternative assay that could speed availability of influenza vaccines in the event of a future pandemic
Posted: 4/9/2014
User Fee Billable Biologic Products and Potencies Approved Under Section 351 of the PHS Act
Updated: 4/9/2014
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
